Avata Biosciences

Curated by Signal

Developer of cannabinoid medicines for neurological diseases

Overview

Developer of cannabinoid medicines for neurological diseases. It offers water soluble solid doses which include SAP-021 for epilepsy, Schizophrenia, Opioid Sparing, and addiction.

Key facts

Founded: 2023
Headquarters: New York City, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

4 products and services: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Medwave
Developer of medical device for monitoring of blood pressure.
Life Sciences TechnologyDanvers, United States
EVQLV
Developer of immunotherapies for cancer and immune diseases
Life Sciences TechnologyNew York City, United States
Cardiac Profiles
Wearable cardiac monitoring device
Life Sciences TechnologyNashville, United States

About Avata Biosciences

What does Avata Biosciences do?

Developer of cannabinoid medicines for neurological diseases.

Where is Avata Biosciences headquartered?

Avata Biosciences is headquartered in New York City, United States.

When was Avata Biosciences founded?

Avata Biosciences was founded in 2023.

Which sector is Avata Biosciences in?

Avata Biosciences operates in Life Sciences Technology.

Who are Avata Biosciences's competitors?

Companies similar to Avata Biosciences include Medwave, EVQLV, and Cardiac Profiles.